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The development of an altered stromal microenvironment is a common feature of many tumours including squamous cell carcinoma
(SCC), and there is increasing evidence that these changes in the stroma, which include increased expression of proteases and
cytokines, may actually promote tumour progression. A common finding is that stromal fibroblasts become ‘activated’ myofibroblasts,
expressing smooth muscle actin and secreting cytokines, proteases and matrix proteins. We show that myofibroblasts are commonly
found in the stroma of oral SCC and are often concentrated at the invasive margin of the tumour. Using oral SCC cells and primary
oral fibroblasts, we demonstrate that tumour cells directly induce a myofibroblastic phenotype, and that this transdifferentiation is
dependent on SCC-derived TGF-b1. In turn, myofibroblasts secrete significantly higher levels of hepatocyte growth factor/scatter
factor compared with fibroblast controls, and this cytokine promotes SCC invasion through Matrigel, a mixture of basement
membrane proteins. This is the first time that this double paracrine mechanism has been demonstrated between squamous
carcinoma cells and fibroblasts, and emphasises that cancer invasion can be promoted indirectly by the release of tumour-induced
host factors from stroma.
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Historically, most studies of neoplastic transformation and
progression have focused on the tumour cell. However, in addition
to transformed cells, tumours are also composed of host stromal
tissue comprising fibroblasts, newly formed blood vessels,
extracellular matrix and immune components. Although stroma
was initially thought to support tumour development passively,
there is increasing evidence to suggest that it actively
contributes to malignant progression (Liotta and Kohn, 2001;
Pupa et al, 2002).
A common finding in many types of solid tumours is that
stromal fibroblasts become ‘activated’ and express a number of
contractile proteins, particularly a-smooth muscle actin (SMA)
(Tlsty and Hein, 2001). These cells have been referred to as
peritumour fibroblasts, carcinoma-associated fibroblasts and
activated stroma, but are now more commonly called myofibro-
blasts (MF). The process of activation of fibroblasts is associated
with increased proliferation, increased deposition of collagen
and spliced-variant forms of fibronectin, assembly of
vinculin-containing fibronexus adhesion complexes and
acquisition of smooth muscle cell characteristics. In fact, it is the
expression of SMA that is the hallmark of the myofibroblastic
phenotype. The structural changes, such as assembly of
fibronexi, and accumulation of cytoskeletal SMA, modulate MF
contractility and reduce their migratory potential (Serini and
Gabbiani, 1999). Conversely, myofibroblasts upregulate the secre-
tion of numerous growth factors, chemokines and cytokines, as
well as extracellular matrix proteins and proteases (Powell et al,
1999a,b).
A number of cytokines including PDGF, IL-4, insulin-like
growth factor II and TGF-b1 may be involved in the transdiffer-
entiation of fibroblasts to myofibroblasts, and these can be derived
from a number of different cell types (Powell et al, 1999a,b).
Among these cytokines, TGF-b1 is considered to have a central
role in inducing the myofibroblastic phenotype, because it is
capable of upregulating fibroblast SMA and collagen both in vitro
and in vivo (Tuxhorn et al, 2001). Indeed, high levels of the
cytokine are usually associated with MF-containing lesions (Tuan
and Nichter, 1998). In many types of cancers, TGF-b1i s
overexpressed by carcinoma cells (Ronnov-Jessen et al, 1996;
Rowley, 1998), and it has been proposed previously that the
expression of this cytokine by breast and prostate carcinoma
cells induces reactive stroma (Ronnov-Jessen et al, 1996;
Rowley, 1998; Webber et al, 1999). TGF-b1 has many effects:
In addition to inhibiting epithelial cell proliferation, it also
promotes the secretion of matrix proteins and proteases. Its
powerful antiproliferative effect has led to it being thought of
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yas a tumour suppressor in carcinomas. However, it is now
apparent that TGF-b1 may be pro-oncogenic, driving malignant
progression, invasion and metastasis (Wakefield and
Roberts, 2002). This is partly explained by observations
of carcinomas, including oral SCC, which become refractory
to the antiproliferative effect of TGF-b1. However, another
mechanism by which TGF-b1 could promote tumour development
is by inducing the transdifferentiation of stromal fibroblasts,
producing an activated, myofibroblast-rich stromal microenviron-
ment. For example, it has been shown that TGF-b1 produced
by breast cancer cells activates normal breast stromal fibroblasts
and promotes them to produce urokinase-type plasminogen
activator, a serine protease important in cancer cell invasion
and metastasis (Sieuwerts et al, 1998). Such changes have a
potential role in tumorigenesis since, if tumour stroma becomes
activated and immobilised in the vicinity of tumour cells,
paracrine interactions may be established between the separate
cellular compartments, some of which could encourage tumour
development.
To date, there has been little work investigating potential
interactions between squamous carcinomas (SCC) and the
surrounding stroma. Maas-Szabowski et al (2001) showed that
IL-1 produced by epidermal keratinocytes induced the expression
of keratinocyte growth factor by dermal fibroblasts, which in turn
stimulated keratinocyte proliferation. It has also been suggested
that PDGF-activated stromal cells may maintain elevated keratino-
cyte proliferation via a paracrine mechanism (Skobe and Fusenig,
1998). Ramos et al (1997) demonstrated that peritumour
fibroblast-conditioned medium promoted SCC migration on
tenascin, and that this effect could be partially inhibited by
blocking EGF, TGF-b1 or hepatocyte growth factor/scatter factor
(HGF/SF). In addition, paracrine interactions have been
demonstrated between squamous carcinoma cells and other cell
types found in stroma. Liss et al (2001) found tumour-derived
TGF-b1 and monocyte chemotactic protein-1 attracted and
activated monocytes. They suggested that macrophages secreted
TNF-alpha and IL-1, which in turn stimulated tumour cells to
produce IL-8 and VEGF, the latter cytokine then inducing
angiogenesis.
The aim of the study was to investigate the role of
squamous carcinoma cells in myofibroblast transdifferentiation,
to determine the effect of such cells on SCC invasion
and to elucidate the possible mechanisms involved in these
processes.
We show that myofibroblasts are commonly found within the
stroma of squamous carcinoma in vivo, particularly at the invasive
front. We demonstrate that squamous carcinoma cells may directly
induce a myofibroblast phenotype in primary fibroblasts through
the secretion of TGF-b1. Furthermore, such transdifferentiated
myofibroblasts significantly upregulate the secretion of hepatocyte
growth factor (HGF/SF), which promotes SCC invasion through
basement membrane proteins. These in vitro data are consistent
with the possibility that a similar double paracrine effect may also
exist in vivo.
MATERIALS AND METHODS
Antibodies and reagents
Six monoclonal antibodies (mAbs) (all of mouse origin) were used
in this study. Antibodies were purchased against human TGF-b1,
HGF/SF (R&D Systems, Abingdon, UK), c-met and phosphorylated
c-met (Upstate Ltd, Milton Keynes, UK) and SMA (Sigma, Dorset,
UK; DAKO, High Wycombe, UK). W632 (anti-MHC class I) was a
kind gift from W Bodmer (IMM, Oxford). FITC-conjugated rabbit
anti-mouse immunoglobulin was purchased from DAKO (High
Wycombe, UK). Recombinant human TGF-b1 was purchased from
R&D Systems, Abingdon, UK. Matrigel was obtained from Becton
Dickinson (Oxford, UK).
Immunohistochemistry
Sections (3mm) were dewaxed, brought to absolute alcohol and
endogenous peroxidase neutralised with 0.5% methanolic hydro-
gen peroxide for 10min. Sections were washed in water, followed
by 0.05% Tween 20 in TBS pH 7.4 (TBS/Tween). Primary anti-SMA
antibody was applied for 60min at a dilution of 1:150 (Dako, High
Wycombe, UK). Sections were again washed in TBS/Tween and
secondary antibody applied for 30min (Dako K5001 ChemMate
HRP/DAB kit). Sections were washed in TBS/Tween and perox-
idase-labelled streptavidin was applied for 30min (Dako K5001).
The peroxidase was visualised using DAB (Dako K5001) for 7min
and counterstained in Mayer’s haematoxylin. In all, 15 archival
oral SCCs and 10 benign polyps showing fibroepithelial hyperpla-
sia were chosen at random, stained for SMA and scored by two
pathologists independently (PMS and GJT), according to the
Quickscore method (Lee et al, 2002). Briefly, the staining intensity
was scored out of 3 (1¼weak, 2¼moderate, 3¼strong), and
the proportion of the stroma in or adjacent to the tumour
staining positively was scored out of 4 (1¼o25%, 2¼25–50%,
3¼51–75%, 4¼76–100%). The score for intensity was added to
the score for proportion to give a score in the range of 0–7 and
grouped as –(score¼0), þ(score¼1–3), þþ(score¼4–5) or
þþþ(score¼6–7). Pathologists agreed completely in 11 of the
15 cases of SCC. The remaining four cases were reanalysed and a
consensus score agreed. Staining of benign polyps for
SMA-positive myofibroblasts was uniformly negative.
Cell culture
Human primary oral fibroblasts (OF) had been established
previously in the laboratory from redundant human tissue
obtained during routine periodontal surgery at the Eastman
Dental Hospital. Oral fibroblasts were maintained in fibroblast
growth medium. This consisted of D-MEM (Life Technologies,
Gibco BRL, Paisley, UK) supplemented with 10% foetal calf serum
(FCS; PAA Laboratories, Yeovil, UK) plus penicillin (100Uml
 1)
and streptomycin (100mgml
 1) (Life Technologies). Cells were
maintained in a humidified atmosphere of 5% CO2 at 371C and
routinely passaged using tryspin–EDTA (Life Technologies). A
panel of three oral SCC cell lines were used. We generated the
invasive VB6 cell line previously by transfection and retroviral
infection of integrin subunits to express high levels of the integrin
avb6 (Thomas et al, 2001b). CA1 and 5PT were kind gifts from
Professor IC Mackenzie (Cardiff dental School, UK). Cells were
grown in standard keratinocyte growth medium (KGM) as
described (Sugiyama et al, 1993). Keratinocyte growth medium
comprised a-MEM containing 10% FCS (Globepharm, Surrey)
supplemented with 1.8 10
 4 M adenine, 5mgml
 1 insulin,
0.5mgml
 1 hydrocortisone and 10ngml
 1 epidermal growth
factor (Sigma).
Preparation and use of medium conditioned by SCCs
(SCCM)
Squamous carcinoma cells were grown to 70% confluence in KGM
in 80cm
2 culture flasks, washed twice with phosphate-buffered
saline (PBS; Life Technologies) and incubated for 72h with 10ml
of a-MEM. The SCCM from each cell line was collected, clarified by
centrifugation and the cells were detached with trypsin/EDTA and
counted. A total of 1.5 10
3 OFcm
 2 were plated in fibroblast
growth medium in 80cm
2 culture flasks or on glass coverslips for
3 days, then washed twice with PBS and incubated for 72h with
a-MEM, SCCM (at equal volumes keratinocyte cell number
 1)o r
a-MEM containing TGF-b1 (R&D Systems, Abingdon, UK;
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 1). For blocking studies, anti-TGF-b1 antibody (R&D
Systems; 1mgml
 1) or a control antibody (W632; anti-MHC type 1;
1mgml
 1) was added to the SCCM for 30min prior to incubation
with the fibroblasts. All experiments were performed in triplicate
and the experiments were repeated four times.
Preparation and use of medium conditioned by fibroblasts
and myofibroblasts
A total of 1.5 10
3 fibroblastscm
 2 were plated in fibroblast
growth medium in 80cm
2 culture flasks for 3 days and then
washed twice with PBS. To induce a myofibroblast, phenotype cells
were incubated for 72h with a-MEM containing recombinant TGF-
b1 (R&D Systems, Oxford, UK), which was acid-activated prior to
use (4mM HCl/0.1% BSA). TGF-b1 was titrated at concentrations
ranging from 0.5 to 10ngml
 1, with maximum SMA induction
observed at 10ngml
 1. This concentration was then used routinely
in all experiments. Control cells were cultured in a-MEM alone.
Cells were also incubated for 72h with SCCM (at equal volumes/
keratinocyte cell number). The cells were washed twice with PBS
and cultured for a further 72h in a-MEM. The control fibroblast-
(FCM) or myofibroblast-conditioned medium (MCM) was col-
lected, clarified by centrifugation and the cells were detached and
counted. The volumes of FCM and MCM were corrected for cell
number, adjusted to a total volume of 500ml and used in the lower
chamber of a Transwell invasion assay as a chemoattractant, or
assayed by ELISA for HGF/SF.
Immunoflourescence microscopy
Primary fibroblasts grown on glass coverslips were treated with
SCCM and a-MEM (7TGF-b1) for 72h. For blocking studies, anti-
TGF-b1 antibody (R&D Systems; 1mgml
 1) or a control antibody
(W632; anti-MHC type 1; 1mgml
 1) was added to the SCCM for
30min prior to incubation with the primary fibroblasts. The cells
were prefixed in 2% paraformaldehyde (BDH), rinsed in PBS, fixed
with methanol (BDH) for 10min at  201C, permeabilised in 0.25%
Triton (Sigma) in PBS and labelled by indirect immunostaining.
Primary anti-SMA antibody (Sigma, clone IA4) was used at a
concentration of 1:1000, while the secondary antibody was FITC-
conjugated rabbit anti-mouse immunoglobulin (Dako, High
Wycombe, UK; 1:500). Nuclei were visualised using DAPI
(Sigma). Images were captured using a Cohu CCD camera attached
to a Leica DM IRB microscope (Leica Microsystems (UK) Ltd,
Milton Keynes, UK).
ELISA
ELISA kits for TGF-b1 and HGF/SF were purchased from R&D
Systems (Oxford, UK). The assay is based on a two site ELISA
‘sandwich’ format. Cell supernatants were prepared as for
conditioned medium and TGF-b1 activated by adding 0.1ml of
1 M HCL for 10min. This was neutralised with 100ml of 1.2 M
NaOH/0.5 M HEPES. Sample (200ml) was added to each well and
TGF-b1 or HGF/SF detected by a peroxidase-labelled FAb0
antibody directed to either cytokine. The reaction was stopped
by the addition of an acid solution and the resultant colour change
was read at 450nm on a spectrophotometer. The concentration
was determined by interpolation from a standard curve using
known concentrations of TGF-b1 or HGF/SF standards as
supplied.
Immunoblotting
Cells of equal confluence were lysed with SDS lysis buffer
containing protease inhibitors (1% SDS, 10mM Tris, pH 7.4,
leupeptin 100mgml
 1, phenylmethylsulphonyl fluoride
100mgml
 1, aprotinin 100mgml
 1) and the protein was estimated
using the BCA protein assay reagent (Pierce Warriner). Samples
containing equal protein were boiled in reducing buffer
(0.5 M Tris-HCl pH 6.8, 10% SDS, 10% glycerol, 0.4% bromophenol
blue, 10% b-mercaptoethanol) and electrophoresed in 10%
SDS–PAGE gel. Protein was electrotransferred onto nitrocellulose
membranes (Hybond-C, Amersham, UK) in transfer buffer
(20mM glycine, 25mM Tris, 0.6mM SDS, 10% methanol) for
12h at 26mV. To prevent nonspecific binding, blots were blocked
for 1h at room temperature in 5% skimmed milk powder
(Marvels, Cadbury, UK) in PBS 0.1% Tween. Anti-SMA antibody
(Sigma; clone 1A4; 1:1000 dilution), anti-c-met antibody
(Upstate Ltd, UK; 1:750 dilution) and antiphosphorylated c-met
(Upstate Ltd, UK; 1:500 dilution) were used for immunoblotting.
Horseradish peroxidase-conjugated anti-mouse was used as
Table 1 SMA staining intensity was assessed semiquantitatively using the Quick score (range 1–7) (Lee et al, 2002) by two pathologists independently
(PMS and GJT)
Site Differentiation Primary, tumour, size
a Stage SMA expression
1 FOM Mod T4 IV +++
2 Tongue Mod T2 II +++
3 FOM Mod T4 IV +++
4 Tongue Well T3 III +
5 FOM Mod T4 IV ++
6 Retromolar Poor T4 IV  
7 Alveolar mucosa Mod T4 IV ++
8 Tongue Poor T4 IV ++
9 FOM Mod T4 IV ++
10 FOM Mod T4 IV ++
11 Tonsillar fossa Poor T4 IV +++
12 Tongue Mod T3 IV +++
13 Tongue Mod T1 III +
14 FOM Mod T4 IV ++
15 Tongue Mod T1 IV +
The SMA staining intensity was scored out of three (1¼weak, 2¼moderate, 3¼strong) and the positive proportion of the stroma in or adjacent to the tumour was scored out
of four (1¼o25%, 2¼25–50%, 3¼51–75%, 4¼76–100%). The score for intensity was added to the score for proportion to give a score in the range of 0–7 and grouped
as  (score¼0),+(score¼1–3), ++(score¼4–5) or +++(score¼6–7). Of the 15 tumours examined, 11 (73%) contained a significant proportion of strongly SMA-positive
stromal cells, indicating myofibroblastic differentiation.
aTumour size T1¼o20mm; T2¼20–40mm; T3¼440mm, T4¼tumour with extension to involve adjacent
structures. SMA¼a-smooth muscle actin. FOM¼floor of mouth.
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with the ECL Western blotting detection kit system (Amersham,
UK). Blots were also probed for b-actin as an additional loading
control. These experiments were repeated a minimum of three
times.
Invasion assays
Cell invasion assays were performed using Matrigel-coated
polycarbonate filters (8mm pore size, Transwell
s, Beckton
Dickinson) as described previously (Thomas et al, 2001a). Matrigel
(70ml; 1:2 dilution in a-MEM) was added to the upper membrane
and allowed to gel for 1h at 371C. Fibroblast conditioned medium
or MCM was corrected for cell number, adjusted to a final volume
of 500ml with a-MEM and used as a chemoattractant in the lower
chamber of the Transwell. For blocking experiments, the condi-
tioned media were incubated with anti-HGF/SF antibody (R&D
Systems; 10mgml
 1) for 30min at 41C prior to placing in the assay.
An irrelevant antibody (W632; anti MHC-type I; 10mgml
 1) was
used as a control. Squamous carcinoma cells were plated in the
upper chamber of quadruplicate wells at a density of 5 10
4 in
200mlo fa-MEM and incubated at 371C for 72h. The cells in the
lower chamber (including those attached to the undersurface of the
membrane) were then trypsinised and counted on a Casy 1 counter
(Sharfe System GmbH, Germany). Experiments were repeated four
times in quadruplicate.
Statistical analysis
Data are expressed as the mean7s.d. of a given number of
observations. Where appropriate, one-way analysis of variance
(ANOVA) was used to compare multiple groups. For comparisons
between groups, Fisher’s PLSD (set at 5% significance) was used. A
P-value of o0.05 was considered to be significant.
Figure 1 Stroma of oral SCC contains prominent myofibroblasts in vivo. Immunohistochemistry showing SMA expression by myofibroblasts in oral SCC
and lack of expression in benign fibroepithelial hyperplasia. (A) Islands of SCC scattered throughout a myofibroblastic stroma with prominent SMA
expression (magnification¼ 100). (B) A single island of SCC surrounded by SMA-positive myofibroblasts (magnification¼ 400). (C) Smooth muscle
actin expression is concentrated at the tumour margin. Strong SMA expression by myofibroblasts is only detected in the near vicinity of the tumour.
Consequently, the margin of the carcinoma appears sharply defined where it abuts ‘normal’ fibroblastic tissue (magnification¼ 100). (D–F) Strong
induction of SMA expression immediately adjacent to islands of SCC (magnification¼ 200,  400,  400, respectively). This was usually seen adjacent to
the invasive margin at the tumour periphery. (G–I) Lack of SMA expression in fibroblasts of benign fibroepithelial hyperplasia (magnification¼ 100,
 200,  400, respectively). The arrow in (I) indicates positive SMA staining of smooth muscle in the wall of a blood vessel, which serves as an internal
positive control.
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Myofibroblastic differentiation is commonly seen in the
stroma of SCCs in vivo, particularly at the invasive front
of the tumour
Of the 15 oral SCCs examined, 11 (73%) contained a significant
proportion of strongly SMA-positive stromal cells, indicating
myofibroblastic differentiation (Table 1). Four tumours contained
focal areas of strong stromal SMA expression. No tumour was
completely SMA negative, and myofibroblastic stromal differentia-
tion was seen in all tumour grades and stages. Although variation in
myofibroblast distribution was seen between different tumours, this
did not correlate with tumour grade or architecture. Figure 1 shows
the prominence of myofibroblasts in the tumour stroma. Such cells
were usually concentrated at the invasive margin of the tumour,
directly abutting malignant epithelial cells (Figure 1C). Stromal
SMA expression often demarcated the margin of the tumour
(Figure 1C) and was only observed in close proximity to the tumour
mass (Figure 1D), even in tumours containing a diffuse inflamma-
tory infiltrate. This suggests that in oral SCC myofibroblasts may be
induced primarily by tumour cells. In addition, 10 benign mucosal
Figure 2 Squamous carcinoma-conditioned medium (SCCM) induces fibroblast SMA expression that is TGF-b1 dependent. (A) Western blot showing
SMA expression by fibroblasts (Fib) compared with myofibroblasts, which had been generated by culture with exogenous recombinant TGF-b1 or SCCM
from the SCC cell lines, b-actin was used as a loading control. (B–D) Western blots showing that the induction of SMA expression by SCCM from VB6 (B),
CA1 (C) and 5PT (D) cells could be inhibited significantly by a TGF-b1 blocking antibody. An irrelevant antibody (W632; anti-MHC type I) was used as a
control. This confirmed that generation of the myofibroblastic phenotype was TGF-b1 specific. The figures show representative experiments. b-actin was
used as a loading control. (E) ELISA confirming that the SCC cell lines secrete TGF-b1. Squamous cell carcinoma cell lines VB6, CA1 and 5PT were cultured
in a-MEM for 72h. The conditioned medium was adjusted for cell number, acid activated and analysed by ELISA for total TGF-b1. 5PT cells secreted
significantly higher levels of TGF-b1 compared with VB6 and CA1 cells. The figure shows representative experiments performed in triplicate. Error bars
represent s.d.
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ypolyps were stained for SMA expression to determine whether
hyperplastic (but non-malignant) squamous epithelium could also
induce SMA induction in adjacent fibroblasts. Although positive
staining of blood vessel smooth muscle was observed (Figure 1I
arrow), no polyp contained SMA-positive myofibroblasts in the
connective tissue (Figure 1(G, H and I).
Squamous carcinoma cells induce myofibroblast
differentiation through secretion of TGF-b1
Human gingival fibroblasts expressed low levels of SMA in culture
(Figure 2A, 3A). Immunostaining showed occasional cells with
weak, diffuse cytoplasmic expression of the protein (Figure 3A).
Treatment of primary fibroblasts with exogenous-activated TGF-
b1 (at concentrations ranging from 0.5 to 10ngml
 1) produced a
significant increase in SMA expression (data not shown).
Maximum SMA expression was observed at a concentration of
10ngml
 1 (Figures 2A and 3B). Figure 3B demonstrates increased
intensity of SMA staining and shows that the protein is now
associated with cytoplasmic stress fibres. SMA upregulation was
also observed when primary fibroblasts were cultured in condi-
tioned medium from VB6, CA1 and 5PT cell lines squamous
carcinoma cell lines (SCCM) (Figures 2A and 3C–H).
ELISA on SCCM confirmed that the SCC cell lines produced
TGF-b1 (Figure 2E), the highest levels secreted by 5PT cells. In
order to determine the proportion of activated TGF-b1 in the SCC
supernatants, we repeated the ELISA comparing acid-activated
conditioned medium (in which all TGF-b1 is in active form) with
untreated samples. In conditioned media from VB6, CA1 and 5PT
cells, we found that the proportion of activated TGF-b1 relative to
total TGF-b1 was 87, 81 and 59%, respectively. In addition,
however, fibroblasts probably activate TGF-b1, and thus the initial
amount of activated cytokine in the SCC medium, before it is
placed onto the fibroblasts, may not be relevant to its eventual
biological effect.
To demonstrate that the generation of a myofibroblastic
phenotype was TGF-b1-dependent, we carried out blocking studies
using a TGF-b1 inhibitory antibody that blocks the biological
activity of activated TGF-b1. Figures 2B–D and 3I–K demonstrate
that when TGF-b1 inhibitory antibody was added to SCCM from
Figure 3 Squamous carcinoma conditioned medium induces fibroblast SMA expression that is TGF-b1 dependent. Fibroblasts grown on glass coverslips
were treated for 72h with a-MEM, a-MEM containing TGF-b1 (10ngml
 1) or SCCM from each cell line. For blocking studies, anti-TGF-b1 antibody
(1mgml
 1) was added to the SCCM for 30min prior to treating the fibroblasts. Smooth muscle actin (green staining) was detected using mouse mAb IA4
(Sigma) with an FITC-conjugated rabbit anti-mouse secondary antibody (Dako). Nuclei (blue staining) were visualised using DAPI (Sigma). Images were
captured using a Leica DC200 digital camera attached to a Leica DM IRB microscope (Leica Microsystems (UK) Ltd, Milton Keynes, UK).
Magnification¼ 20 (A–E),  40 (F–H),  60 (I–K). The figure shows occasional weak diffuse cytoplasmic SMA staining in control fibroblasts treated
with a-MEM only (A). SMA expression is strongly upregulated in fibroblasts treated with recombinant TGF-b1 (10ngml
 1; B) or SCCM from each cell line
(VB6¼C, F; CA1¼D, G; 5PT¼E, H). In each instance, SMA is organised into stress fibres. The addition of inhibitory TGF-b1 antibody to SCCM
prevented SMA upregulation (VB6¼I, CA1¼J, 5PT¼K), confirming that the induction of the myofibroblast phenotype was TGF-b1 specific.
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of SMA expression was reduced significantly (as determined by
densitometric scanning; by 65%, P¼0.0297; 75%, P¼0.0028; 82%,
P¼o0.0005, respectively). These data were confirmed by
immunofluorescence, which showed only a weak diffuse cytoplas-
mic staining for SMA with no stress fibre formation when TGF-b1
was inhibited (Figure 3I–K).
MCM promotes invasion of SCC cells
To determine whether myofibroblasts secrete factors, which
stimulate the invasion of squamous carcinoma cell lines, we
carried out transwell assays through Matrigel. Myofibroblasts were
generated using either TGF-b1 or SCCM from each cell line, and
then cultured for 72h in a-MEM. The MCM was used as a
chemoattractant in the lower chamber of the Transwell and SCC
cells were allowed to invade towards this stimulus for 72h before
being counted. Primary FCM was used for comparison. We
demonstrate that MCM significantly promoted invasion of VB6,
CA1 and 5PT cells compared with FCM (Figure 4A; P¼o0.0001,
o0.0001, 0.0005, respectively). Myofibroblasts-conditioned med-
ium from myofibroblasts generated using exogenous recombinant
TGF-b1 (10ngml
 1) produced a similar level of invasion as MCM
from myofibroblasts generated by SCCM from each of the cell lines
(Figure 4A). If TGF-b1 was inactivated using a blocking antibody
added to SCCM, no transdifferentiation of myofibroblasts was seen
(Figure 3I–K), and conditioned medium from such cells (which
remained fibroblasts) no longer promoted invasion (Figure 4B). To
ensure that altered cell invasion was not simply due to increased
cell proliferation, growth assays were performed in which SCC cells
were grown in MCM or FCM for 72h. The cell proliferation was
low (due to the absence of serum in FCM and MCM) and no
differences in growth rate were observed.
Myofibroblasts upregulate secretion of HGF/SF
Previously, several studies have demonstrated that myofibroblasts
may secrete HGF/SF (Bradbury, 1998; Goke et al, 1998). This
cytokine acts to promote epithelial cell growth and migration and
has been shown to stimulate invasion in prostate carcinoma cells
(Nishimura et al, 1999). To determine whether induction of a
myofibroblastic phenotype was associated with increased produc-
tion of HGF/SF, we examined conditioned medium by ELISA.
Myofibroblasts were generated using either exogenous TGF-b1o r
SCCM from each SCC cell line. Untreated primary fibroblasts were
used as a control. Figure 5 demonstrates that MCM contains
significantly higher levels of HGF/SF compared with FCM (up to
35-fold higher). Myofibroblasts that had been generated using
conditioned medium from all three SCC cell lines consistently
showed a significant upregulation of HGF/SF secretion when
compared with primary fibroblast controls (VB6, P¼0.0063; CA1,
P¼0.0003; 5PT, P¼o0.0001). Secreted HGF/SF levels were
generally higher in myofibroblasts, which had been generated
with conditioned medium from the 5PT cell line. This was
probably due to the higher levels of TGF-b1 produced by this line
(Figure 2E).
Figure 4 Myofibroblast conditioned medium (MCM) promotes invasion of SCC cells. Cell invasion assays were performed over 72h using matrigel-
coated polycarbonate filters. Conditioned medium from myofibroblasts that had been generated with recombinant TGF-b1 (grey-filled histogram) or SCCM
(black-filled histogram) was used as a chemoattractant in the lower chamber of the Transwell. This was compared with FCM white-filled histogram).
Following incubation, the cells in the lower chamber (including those attached to the undersurface of the membrane) were trypsinised and counted on a
Casy 1 counter (Sharfe System GmbH, Germany). The figure shows a representative experiment performed in quadruplicate. Error bars represent s.d. (A)
Myofibroblast-conditioned medium significantly promoted invasion of VB6, CA1 and 5PT cell lines. In comparison, little invasion was seen when FCM was
used. Results are expressed relative to VB6 invasion using SCCM-generated MCM (¼100). (B) Fibroblasts treated with SCCM containing an inhibitory
TGF-b1 antibody did not show myofibroblast transdifferentiation. Conditioned medium from such cells (grey-filled histogram) did not promote invasion
compared with MCM (black-filled histogram), where the myofibroblasts were generated with SCCM containing a control antibody, W632. Results are
expressed relative to VB6 invasion using SCCM-generated myofibroblast conditioned medium (¼100).
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invasion of squamous carcinoma cells
To determine whether HGF/SF promoted invasion in the Transwell
assays, we carried out blocking experiments using inhibitory
antibodies directed against HGF/SF, which were added to the
MCM. Figure 6A confirms that the three SCC cell lines expressed
the HGF/SF receptor c-met. Figure 6D demonstrates that inactiva-
tion of HGF/SF significantly reduced the invasion of VB6, CA1 and
5PT cells through Matrigel (P¼0.0014, 0.0159, 0.0012, respec-
tively). Following HGF/SF inhibition, the level of invasion was
similar to that produced by FCM, suggesting that the invasion-
promoting effect of MCM was mediated by HGF/SF.
These data are the first to show that invasion of SCC may be due
partly to a double paracrine effect, resulting in proinvasive release
of HGF/SF from stromal myofibroblasts.
DISCUSSION
Accumulation of fibroblast-like cells, including myofibroblasts, is
frequently observed associated with the edge of an actively
expanding tumour mass (Martin et al, 1996; Emura et al, 2000).
Such a phenomenon has been demonstrated, to different extents,
in a variety of tumours and there is increasing evidence that
tumour stroma may promote tumour progression (Liotta and
Kohn, 2001; Pupa et al, 2002). Interactions between epithelial cells
and fibroblasts have a major role in many biological processes and
it follows that the interactions between tumour cells and
neighbouring myofibroblasts may be biologically significant,
probably mediated by soluble factors such as growth factors and
cytokines. This has been demonstrated previously in breast cancer
where TGF-b1 produced by breast cancer cells activates normal
breast stromal fibroblasts and promotes them to produce proteases
(Ronnov-Jessen and Petersen, 1993; Sieuwerts et al, 1998). Similar
interactions have been shown in prostatic carcinomas (Olumi et al,
1999; Webber et al, 1999), and in the fibrosis observed in organs
such as the kidney (Lewis and Norman, 1998) and liver (Kinnman
and Housset, 2002).
In the present study, we examine potential interactions between
squamous carcinoma cells and primary fibroblasts. We show that
stromal cells in SCC in vivo often express SMA, indicating a
myofibroblastic phenotype (Table 1; Figure 1). Such cells are most
commonly found at the invasive margin, directly abutting tumour
cells but are absent in areas distant from tumour. Furthermore,
myofibroblasts were not detected in benign mucosal polyps. These
data are consistent with the possibility of a tumour-derived,
diffusible factor that promotes fibroblast-to-myofibroblast trans-
differentiation.
A number of cytokines including PDGF, IL-4, insulin-like
growth factor II and TGF-b1 may be involved in the transdiffer-
entiation of fibroblasts to myofibroblasts, and these can be derived
from several cell types. In addition, mast cell-derived histamine
and tryptase has been reported to induce SMA expresson in
fibroblasts (Gailit et al, 2001). However, it is generally accepted
that TGF-b1 has a key role in inducing myofibroblast differentia-
tion, and high levels of the cytokine are usually associated with
MF-containing lesions (Tuan and Nichter, 1998). TGF-b1i s
frequently detectable in SCC, particularly in the more advanced
stages of tumour progression, and relatively high concentrations of
TGF-b1 are usually found in tumour stroma (Pasche, 2001).
Recently, Bauer et al (2002) showed that keratinocytes genetically
modified to produce activated TGF-b1 induced collagen type I
gene expression in dermal fibroblasts in a coculture system. The
role of TGF-b1 in SCC is complex and studies suggest that TGF-b1
has biphasic actions on tumour cells, having an important negative
growth effect in the early stages of carcinogenesis, but at later
stages enhancing invasion and metastasis through epigenetic
mechanisms (Akhurst and Balmain, 1999; Akhurst and Derynck,
2001). However, most studies have concentrated on the direct
effect of TGF-b1 on tumour cells. Our data suggest that a possible
indirect tumour-promoting effect of SCC-derived TGF-b1 may be
in generating a myofibroblastic stroma, which in turn modulates
invasion in a paracrine manner.
Myofibroblasts may promote tumour progression in a number
of different ways. They upregulate the expression of serine and
matrix metalloproteinases, which degrade and remodel extracel-
lular matrix, possibly potentiating cell invasion and migration
(Sieuwerts et al, 1998). In addition, Ramos et al (1997) showed that
peritumour FCM upregulated the expression of the integrin avb6
in SCC cells, and we have previously demonstrated that de novo
expression of this integrin promotes invasion of oral carcinoma
(Thomas et al, 2001a,b). Myofibroblasts also secrete interstitial
matrix, as well as numerous soluble mediators of inflammation
and growth factors, including HGF/SF (Powell et al, 1999a,b). The
latter cytokine was originally identified as a potent mitogen for
hepatocytes, but was also identified independently as a scatter
factor (SF), a secretory protein of fibroblasts and smooth muscle
cells that dissociates and induces motility of epithelial cells. Scatter
factor and HGF were later found to be identical, hence the current
name HGF/SF. The cytokine modulates its effects through the c-
met tyrosine kinase receptor and misregulated expression of both
cytokine and receptor is a common finding in many tumour types
Figure 5 Myofibroblasts upregulate secretion of hepatocyte growth
factor (HGF/SF). Myofibroblasts were generated using either exogenous
TGF-b1 or SCCM from each SCC cell line. Untreated fibroblasts were
compared as a control. Supernatants were collected from the cells after
72h, corrected for cell number and analysed by ELISA for HGF/SF. ELISA
demonstrating that MCM contains significantly higher levels of HGF/SF
compared with FCM. Myofibroblasts generated using conditioned medium
from all three SCC cell lines consistently showed a significant upregulation
of HGF/SF secretion when compared with fibroblast controls. The figure
shows a representative experiment performed in triplicate. Error bars
represent s.d.
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expressed in oral SCC in vivo and in vitro (Bennett et al, 2000;
Morello et al, 2001), it is not commonly mutated to a constitutively
active form, and is not tumour-promoting per se in the absence of
ligand. Hepatocyte growth factor/scatter factor may induce
invasive growth by affecting the activity and expression of
cadherins, integrins and matrix metalloproteinases. This results
in disruption of intercellular junctions, dissolution of epithelial
basement membrane and altered integrin interactions
with extracellular matrix (Trusolino and Comoglio, 2002).
Fibroblast-derived HGF/SF has been shown to stimulate
invasion and migration in a number of tumour types including
squamous cell carcinoma (Matsumoto et al, 1994; Uchida et al,
2001), and we have demonstrated previously that exogenous
HGF/SF induces expression of the type IV collagenases MMP-2
and -9 in squamous carcinoma cells (Bennett et al, 2000).
The latter observation suggests a possible mechanism for the
HGF/SF-dependent invasion through basement membrane-like
Matrigel (which comprises predominantly type IV collagen)
described in this study. In addition, we have shown more recently
that HGF/SF regulates integrin function in oral SCC cells
(Poomsawat et al, 2003).
Figure 6 (A) SCC cell lines express c-met receptor: Western blot showing expression of c-met protein by VB6, CA1 and 5PT cell lines. Control is A431 cell
lysate (Upstate, Milton Keynes, UK). (B) Myofibroblast-conditioned medium induces increased phosphorylation of c-met receptor compared with FCM. Western
blot demonstrating increased phosphorylation of c-met in VB6, CA1 and 5PT cells when incubated with MCM compared with FCM. Cells were serum
starved for 48h, incubated with MCM or FCM for 30min and lysed. Blots were probed with anti-phospho c-met antibody (Upstate Ltd, Milton Keynes, UK),
which recognises specifically the phosphorylated form of the receptor. (C) Densitometric scan of Western blot confirming increased phosphorylation of c-
met in SCC cells treated with MCM. (D) Inactivation of HDF/SF in MCM inhibits invasion of squamous carcinoma cells. Cell invasion assays were performed over
72h using matrigel coated polycarbonate filters. Conditioned medium from myofibroblasts, which had been generated with SCCM were treated with a
control antibody (W632; black-filled histogram) or an HGF/SF-inhibitory antibody (grey-filled histogram) and used as a chemoattractant in the lower chamber
of the Transwell. Fibroblast-conditioned medium (white-filled histogram) was also used in comparison. Following incubation, the cells in the lower chamber
(including those attached to the undersurface of the membrane) were trypsinised and counted on a Casy 1 counter (Sharfe System GmbH, Germany). The
figure shows a representative experiment performed in quadruplicate. Results are expressed relative to VB6 invasion using SCCM-generated myofibroblast
conditioned medium (¼100). Error bars represent s.d. The inactivation of HGF/SF in MCM significantly reduced invasion of VB6, CA1 and 5PT cells.
Following HGF/SF inhibition, the level of invasion was similar to that produced by FCM, suggesting that the invasion-promoting effect of MCM was modulated
through HGF/SF.
Myofibroblasts promote invasion of squamous carcinoma cells
MP Lewis et al
830
British Journal of Cancer (2004) 90(4), 822–832 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ySeveral other paracrine interactions between keratinocytes and
fibroblasts have been demonstrated previously. For example, it has
been suggested that PDGF-activated stromal cells maintain
elevated keratinocyte proliferation via a paracrine mechanism
(Skobe and Fusenig, 1998), and Maas-Szabowski et al (2001)
showed that IL-1 produced by epidermal keratinocytes induced the
expression of KGF by dermal fibroblasts, which in turn stimulated
keratinocyte proliferation. Paracrine interactions have also been
demonstrated between squamous carcinoma cells and other cell
types. Liss et al (2001) found tumour-derived TGF-b1 and
monocyte chemotactic protein-1 attracted and activated mono-
cytes. They suggested that macrophages secreted TNF-alpha and
IL-1, which in turn stimulated tumour cells to produce IL-8 and
VEGF, the latter cytokine-inducing angiogenesis.
In conclusion, this study shows for the first time that a
double paracrine interaction between SCC cells and fibroblasts
can exist that results in enhanced tumour invasion. We show
that SCC-derived TGF-b1 induces a myofibroblastic phenotype
and that such cells secrete significantly higher levels of
HGF/SF compared with primary fibroblast controls. In turn,
HGF/SF promotes invasion of SCC cells through basement
membrane proteins. We also confirm that the myofibroblast
population is usually located adjacent to the invasive front of
SCC. These clinical observations are consistent with the sugges-
tion that the paracrine interactions observed in vitro between
SCC and fibroblasts may also occur in vivo, and emphasises
the importance of the stromal contribution to tumour deve-
lopment.
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